1. Home
  2. RDI vs TXMD Comparison

RDI vs TXMD Comparison

Compare RDI & TXMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

RDI

Reading International Inc

HOLD

Current Price

$1.06

Market Cap

25.7M

ML Signal

HOLD

Logo TherapeuticsMD Inc.

TXMD

TherapeuticsMD Inc.

HOLD

Current Price

$1.98

Market Cap

24.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RDI
TXMD
Founded
1937
2008
Country
United States
United States
Employees
2005
N/A
Industry
Movies/Entertainment
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
25.7M
24.3M
IPO Year
N/A
2012

Fundamental Metrics

Financial Performance
Metric
RDI
TXMD
Price
$1.06
$1.98
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
18.2K
22.6K
Earning Date
05-14-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
73.68
EPS
N/A
N/A
Revenue
N/A
$1,761,000.00
Revenue This Year
$16.25
N/A
Revenue Next Year
$4.04
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
35.25
52 Week Low
$0.94
$0.98
52 Week High
$1.65
$2.95

Technical Indicators

Market Signals
Indicator
RDI
TXMD
Relative Strength Index (RSI) 39.67 39.25
Support Level $0.99 $1.94
Resistance Level $1.16 $2.05
Average True Range (ATR) 0.05 0.12
MACD -0.01 -0.01
Stochastic Oscillator 15.80 12.50

Price Performance

Historical Comparison
RDI
TXMD

About RDI Reading International Inc

Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.

About TXMD TherapeuticsMD Inc.

TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.

Share on Social Networks: